The observed high frequency of EGFR mutations in Asian patients compared with Caucasian populations is a well-known, and NSCLC harboring EGFR mutations or ALK rearrangements are reported to be associated with low efficacy of ICIs39,41–44. Here, EGFR is linked to non-small cell lung carcinoma.